Brilinta, also known as ticagrelor, is associated with several side effects, with bleeding being the most significant. Other common side effects include dyspnea, which is shortness of breath, and increased risk of bruising [1].
What are the most serious side effects of Brilinta?
The most critical side effect of Brilinta is bleeding. This can range from minor bruising to life-threatening hemorrhages [1]. Patients experiencing any signs of abnormal bleeding, such as prolonged nosebleeds, blood in urine or stool, or coughing up blood, should seek immediate medical attention [1]. Another serious concern is dyspnea, or difficulty breathing, which can occur and may require medical evaluation [1].
How common is bleeding with Brilinta?
Bleeding events are a known complication for patients taking Brilinta. While the exact frequency can vary depending on individual patient factors and the specific clinical trial, bleeding is consistently identified as a primary side effect in studies [1].
What other side effects might patients experience?
Beyond bleeding and shortness of breath, patients may experience increased bruising [1]. Other reported side effects can include dizziness, headache, and gastrointestinal issues such as diarrhea [1]. It is important for patients to discuss any new or worsening symptoms with their healthcare provider.
How does Brilinta's side effect profile compare to other antiplatelet drugs?
Compared to clopidogrel (Plavix), Brilinta has been shown to reduce the risk of major adverse cardiovascular events, but it is associated with a higher rate of non-cardiac bleeding and dyspnea [1]. The choice of antiplatelet medication often involves balancing the risk of blood clots against the risk of bleeding and other side effects.
Where can I find more information about Brilinta's patent status and competitors?
Information regarding Brilinta's patent status, including anticipated patent expiry dates and any ongoing patent litigation, can be found on DrugPatentWatch.com [2]. This resource also tracks competing drugs and potential generic or biosimilar entrants in the market.
---
Sources:
[1] DrugPatentWatch.com
[2] https://www.drugpatentwatch.com/